CompletedNCT02473289
Sirukumab Added to Antidepressants for Major Depression
About this title
Read the official source — NCT02473289Medication studyAges 21–64Multiple countries
Understand this study
Who was this study for?
Listed age limits: 21 years to 64 years.
- Listed locations
- Birmingham and 45 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: July 23, 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 193
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada, United Kingdom, ...
- Age range
- From 21 Years to 64 Years
- Official registry ID
- NCT02473289
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a Monoaminergic Antidepressant in Adults With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedBirmingham, United States · Little Rock, United States · Bellflower, United States
44 more locations
- Glendale, United States
- Lemon Grove, United States
- Orange, United States
- Santa Ana, United States
- Torrance, United States
- Wildomar, United States
- Atlanta, United States
- Decatur, United States
- Chicago, United States
- Edgewood, United States
- Baltimore, United States
- Grand Rapids, United States
- Lebanon, United States
- Brooklyn, United States
- New York, United States
- Staten Island, United States
- Columbus, United States
- Oklahoma City, United States
- Houston, United States
- Plano, United States
- Salt Lake City, United States
- Edmonton, Canada
- Chatham, Canada
- Hamilton, Canada
- Toronto, Canada
- Bełchatów, Poland
- Bydgoszcz, Poland
- Chełmno, Poland
- Gorlice, Poland
- Lublin, Poland
- Karelia, Russia
- Moscow, Russia
- Nizny Novgorod, Russia
- Rostov-on-Don, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Saratov Region, Russia
- Tomsk, Russia
- Yaroslavl, Russia
- Edinburgh, United Kingdom
- Glasgow, United Kingdom
- Oxford, United Kingdom
- Redruth, United Kingdom
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Sirukumab 50 mg and Placebo.
Who was this study for?
Listed age limits: 21 years to 64 years.
